Brief: Ceapro Inc Receives Approval From Health Canada To Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets
22/12/2022 14:05
Dec 22 (Reuters) - Ceapro Inc CZO.V :
* CEAPRO INC RECEIVES APPROVAL FROM HEALTH CANADA TO
COMMENCE
PHASE 1/2A HUMAN CLINICAL TRIAL ASSESSING AVENANTHRAMIDE TABLETS
Source text for Eikon: ID:nGNX7vsJs6
Further company coverage: CZO.V
((Reuters.Briefs@thomsonreuters.com))
Recent news on Ceapro
See all newsBrief: Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Brief: Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Brief: Aeterna Zentaris And Ceapro Announce Merger Of Equals To Create Diversified Biopharmaceutical Company
Brief: Ceapro Inc. Reports 2023 Third Quarter And Nine-Month Financial Results And Operational Highlights
Brief: Ceapro Initiates Phase 1-2A Study Assessing Avenanthramides For Potential Applications In Inflammation Based Diseases